The company’s close communication with customers has enabled it to bring advanced pipetting products to market.
INTEGRA Biosciences, a company that develops solutions for pipetting and media preparation, has been engaging with its customers to understand the challenges they face in the laboratory. The close communication enables the company to bring new products-such as the Voyager adjustable tip spacing pipette, GripTips, and the Assist Plus pipetting robot-to the market.
Voyager, an electronic multichannel pipette, offers automatic adjustment of tip spacing for maximum flexibility. To adjust tip spacing, a single-handed push-button is used, which allows for easy parallel transfer of samples, for example from tubes to plates or 96- to 384-well formats. This increases speed and throughput, according to the company.
Evolve pipettes are for laboratories that prefer manual pipetting. They replace the traditional, single-rotating plunger with three number-lock dials that are quickly and easily set to the required volume. GripTips, INTEGRA’s new tip-pipette interface, enables trouble-free tip pick-up, eliminating the pick-up inconsistencies and failures that lead to misalignment across a multichannel pipette, leakage, or even tips falling off. The product’s snap-on design securely attaches the tip to any INTEGRA pipette, ensuring it is properly aligned and sealed, without any additional manipulation.
The company’s products are also ergonomically designed. The Assist and Assist Plus pipetting robots enable automation of repetitive processes, such as serial dilutions, reformatting, and set-up of assay plates. This promotes flexible, reproducible, and error-free pipetting at an affordable price. New applications are accessed simply by swapping to a different INTEGRA pipette, which ensures that the pipette systems do not become obsolete. In addition, the pipettes can still be used manually when needed.
Source: INTEGRA Biosciences
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.